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doi:10.1016/j.kjms.2011.10.007Abstract In order to determine the prognostic impact of lymphovascular invasion (LVI) in
patients after radical prostatectomy, the retrospective data from our institution has been
analyzed. From 1998 to 2010, 117 patients underwent radical prostatectomy. A total of 87
patients were included in this retrospective study. The relationship between LVI and advanced
prostate cancer characteristics was evaluated by c2 test. The Kaplan-Meier method and meta-
analysis were used to describe the impact of LVI invasion upon early biochemical failure after
radical prostatectomy. LVI was observed in patients with clinically or pathologically aggressive
prostate cancer including patients of higher preoperative risk group, higher preoperative PSA,
advanced Gleason grade, and pathological T3 disease. LVI is also associated with early
biochemical failure rate both in our report and in the literature. Therefore, LVI is a pathological
feature which indicates prognosis correlates with aggressive prostate cancer behavior and
results in early biochemical failure after radical prostatectomy.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.of Urology, Kaohsiung Chang
Road, Niaosung, Kaohsiung,
h.org.tw, cphtem@yahoo.
vier Taiwan LLC. All rights reservIntroduction
Radical prostatectomy is thought to be a curative treat-
ment for clinically localized prostate cancer. However,
26e68% of patients are still found to have extraprostatic
disease even after radical prostatectomy [1e3]. Early
biochemical recurrence can be observed in 16e38% of
patients, and it is therefore important to identify patho-
logical features predicting aggressive cancer behaviored.
328 H.L. Luo et al.[4e6]. Further adjuvant therapy may improve biochemical
control and delay cancer progression.
The Gleason score, pathological tumor stage (pT),
surgical margins, or the presence of lymph node metastasis
are generally classically used as prognostic factors of
prostate cancer. Many studies have indicated micro-
environmental factors may influence cancer progression
[7,8]. Lymphovascular invasion (LVI) is easily identified by
pathological review and it has also been reported to be
important for prognosis after radical prostatectomy [9e14].
Validation of the relationship between LVI and aggressive
prostate cancer behavior with pathological or biochemical
results by cohort study is reasonable.
Materials and methods
Patients were retrospectively identified from our institu-
tional database. From 1998 to 2010, 117 patients with
clinically localized prostate cancer received retropubic
radical prostatectomy at our institution. All patients
underwent preoperative staging by abdominal computed
tomography (CT) or magnetic resonance imaging (MRI) and
bone scan to be sure that the disease was organ-confined. A
total of 87 patients with detailed records of preoperative
PSA, clinical staging, pathological staging, Gleason score,
and LVI were included in this study.
The primary end-point was the association of these vari-
ables with biochemical failure, defined as PSA level of more
than 0.2 ng/mL during clinical follow-up. Patients were
divided into two groups for the study: those who had under-
gone radical prostatectomy with or without LVI. Each group
was further subdivided into low-, intermediate-, and high-
risk groups: low-risk group was composed of patients with
a PSA level of<10, a Gleason score of6, or a T-stage of T2a
or lower; intermediate-risk group was composed of patients
with a PSA level of 10e20, a Gleason score of 7, or a T-stage of
T2b; and the high-risk group included those patients with
a PSA level of>20, a Gleason score of8, or a T-stage of T2c
or higher. Aggressive pathological features, such as Gleason
score greater than 7, extraprostatic invasion, and seminal
vesicle involvement were also identified in these two groups.
SPSS v.17 software (SAS Institute, Cary, NC, USA) was
used for statistical analysis. Correlation between theTable 1 Correlation of LVI with clinical and pathological variab
LVI(＋)(nZ 18)
Follow-up (months) 49.8 (5.1e91.8)
Age (year) 61.2 (52e76)
Risk classification
Low-risk group 1 (5.6%)
Intermediate-risk group 1 (5.6%)
High-risk group 16 (88.9%)
Preoperative PSA>20 8 (44.4%)
Gleason score >7 9 (50.0%)
Capsular invasion 14 (77.8%)
Seminal vesicle invasion 10 (55.6%)
Positive surgical margin 10 (55.6%)
Nodal positive disease 2 (11.1%)
5-year biochemical failure 12 (66.7%)distribution of these two groups and comparison of preop-
erative risk group and aggressive pathological features were
analyzed by c2 test; 5-year biochemical failure incidence
was estimated by the Kaplan-Meier method with Log-rank
test. The results were statistically significant if p< 0.05.
Furthermore, meta-analysis was used for review of prog-
nostic impact of LVI in radical prostatectomy specimens.
Results
This retrospective study enrolled 87 patients with clinically
localized prostate cancer. Median age was 63 (range from
49 to 83) and median follow-up duration was 40.9 (range
from 0.6 to 99.9) months. The detailed characteristics
regarding preoperative risk group, advanced Gleason grade,
advanced pathological staging such as capsular penetration
and seminal vesicle involvement, and 5-year biochemical
failure incidence are listed in Table 1.
There were 18 patients with LVI and 69 patients without
LVI as determined by pathological review. Comparing both
groups, a greater number of patients in the LVI group
belonged to preoperative high risk than in the nonLVI group
(88.9% and 44.9%, pZ 0.003). The pathological result
showed that preoperative PSA of more than 20 ng/mL
(44.4% and 15.9%, pZ 0.009), Gleason grade of more than 7
(50.0% and 11.6%, p< 0.001), capsular penetration (77.8%
and 37.7%, p< 0.002), and seminal vesicle involvement
(55.6% and 10.1%, p< 0.001) occurred significantly more
frequently in patients with LVI compared with those
without LVI.
Regarding oncological outcome, a significantly higher
biochemical failure rate was noted in patients with LVI than
in those without LVI (pZ 0.012) (Fig. 1). We reviewed
recent studies with detailed reports concerning biochem-
ical failure incidence related to LVI in radical prostatec-
tomy specimens. The risk ratio of biochemical failure
increased from 1.64 to 7.66 if LVI was present (Table 2).
Discussion
Several clinical studies have indicated that Gleason grade,
capsular penetration, seminal vesicle involvement andles.
LVI()(nZ 69) p value
34.4 (0.6e99.9) 0.101
64 (49e83) 0.746
0.003
7 (10.1%)
31 (44.9%)
31 (44.9%)
11 (15.9%) 0.009
8 (11.6%) <0.001
26 (37.7%) 0.002
7 (10.1%) <0.001
28 (40.5%) 0.185
3 (4.3%) 0.272
28 (40.5%) 0.012
Figure 1. Biochemical failure incidence between LVI and
no LVI.
LVI predicts early prostate cancer recurrence 329surgical margin status could be used as prognostic predic-
tors [3e6]. Pathologists traditionally examine the micro-
scopic features for the urologist to evaluate whether or not
adjuvant therapy is necessary to prevent biochemical
disease recurrence. LVI is a well-established prognostic
factor in many human malignancies, such as breast cancer,
testicular cancer, and renal cell carcinoma. According to
the latest guidelines from the Association of Directors of
Anatomic and Surgical Pathology, LVI was suggested to be
included in the pathological report but currently it is still not
recommended for routine use. However, tumor angiogenesis
was thought to be associated with cancer invasion and thus
distant metastasis. It is reasonable to examine the presence
of LVI and possible further correlations between the cancer
behavior and oncological outcome. The independently
predictive role of LVI has been recently discussed in
biochemical failure after radical prostatectomy [9,10]. TheTable 2 Meta-analysis of literature review about prognostic im
Study or Subgroup LVI positive LVI negative
Events Total Events Total
Herman, 2000 41 91 36 172
de la Taille, 2000 28 30 63 211
Ito, 2003 26 38 7 44
Ferrari, 2004 78 110 153 510
Shariat, 2004 21 32 113 597
Cheng, 2005 11 106 7 353
Loeb, 2006 40 118 159 1591
May, 2007 26 42 47 370
Yee, 2010 49 129 58 1169
Present series 12 18 28 69
Total (95% CI) 714 5086
Total events 332 671
Heterogeneity: Chi2Z 58.24, dfZ 9 (P< 0.00001); I2Z 85%
Test for overall effect: ZZ 22.17 (P< 0.00001)aim of this study was to validate the prognostic impact of LVI
upon prognosis prediction and discuss the relationship
between LVI and prostate cancer behavior.
This study showed that the incidence of LVI in radical
prostatectomy specimens was 20.7%. The incidence (from
5% to 46%) reported in previous studies varies according to
different distribution of preoperative risk group. Patients
with LVI tend to have a significant association with higher
Gleason grade and preoperative PSA [12,15]. A higher
incidence of locally advanced disease related to LVI was
also noted in previous studies [10,12,15,16]. In addition,
early biochemical recurrence or shorter PSA doubling time
could be observed in patients with LVI [17]. Prostate cancer
with higher recurrence potential, such as with higher
preoperative PSA level, higher Gleason grade, capsular
invasion, and seminal vesicle involvement, was found to
occur significantly more frequently in patients with LVI in
this retrospective study.
The presence of nodal positive disease made no differ-
ence in our series. This may have resulted from relatively
small patient numbers in the nodal positive group. The
duration-related incidence of biochemical failure after
radical prostatectomy was significantly higher in patients
with LVI. This indicated the importance of identifying LVI
in pathological reports, and it may provide a valuable
parameter for urologists to arrange further adjuvant therapy.
The possible explanation and current belief for the
correlation between LVI and clinically or pathologically
aggressive prostate cancer is tumor angiogenesis. LVI could
be considered to be a result of aggressive cancer behavior or
an enhancing factor which interacts with the tumor. Further
demonstration of the molecular pathway is worthy of
investigation. For clinical practice, locally advanced disease
does not independently cause poor prognosis and it differs
according to surgical factors and nodal status [18]. Though
the correlation between LVI and locally advanced disease
cannot reflect the impact upon biochemical result directly,
LVI was reported to be an independent predictor of a poorer
biochemical result in recent studies after assessing surgical
and histopathological factors with multivariate analysis
[9e12]. It may be because possible occult distant metastasispact of LVI on prostate cancer.
Risk Ratio Risk Ratio
Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI
14.6% 2.15 [1.49, 3.11]
9.2% 3.13 [2.49, 3.93]
3.8% 4.30 [2.11, 8.77]
31.8% 2.36 [1.98, 2.83]
6.7% 3.47 [2.57, 4.68]
1.9% 5.23 [2.08, 13.16]
12.9% 3.39 [2.53, 4.54]
5.6% 4.87 [3.41, 6.97]
6.8% 7.66 [5.48, 10.69]
6.8% 1.64 [1.06, 2.54]
100.0% 3.19 [2.88, 3.53]
330 H.L. Luo et al.via the lymphatic or vascular systems cannot be actually
identified by radical prostatectomy specimens.
The nonsignificance of positive margin status counter-
balances the effect of surgical factors between these two
groups. The incidence of biochemical failure is still signifi-
cantly higher in patients with LVI in our series. It is not
proven to be an independent predictor by the logistic
regression model and thus a larger patient pool is needed
for validation of this finding. However, the prognostic
significance can still be found under univariate analysis.
Therefore, biochemical failure incidences in other studies
were reviewed in the English literature from 2000 to 2010.
We used the meta-analysis method to identify the hazard
ratio of biochemical recurrence in patients with LVI after
radical prostatectomy. The average risk ratio of biochem-
ical recurrence within 5 years increased up to 3.19 in
patients with LVI as compared to those without LVI. We
recommend that LVI should be routinely included in path-
ological reports due to its prognostic significance.
Several limitations should be considered with regard to
this retrospective study. The result is not independently
conclusive due to the relatively small series. In addition,
the radical prostatectomy was performed by different
surgeons and surgical factors may thus interfere with the
biochemical result. No further reporting was done con-
cerning the extent in a high power field which may have
potential prognostic influence [15]. Specimens were eval-
uated by different pathologists and the diagnostic criteria
of LVI carry subtle differences. Bias correction in a single-
center experience with a single surgeon, a single patholo-
gist, and a detailed description of LVI would provide better
validation of risk.
Conclusion
Lymphovascular invasion can be observed in a proportion of
the radical prostatectomy specimens, especially in high-risk
group patients. It is a prognosis predicting pathological
feature which correlates with aggressive prostate cancer
behavior and results in early biochemical failure after
radical prostatectomy.References
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